Lexicon Pharmaceuticals LXRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 99.4%+1.4pp | 98%+5.1pp | 92.9%-7.1pp | 100%0.0pp | |
| Operating margin | -98.2%+536pp | -634.2%+13,619pp | -14,253.1%+58,236pp | -72,489.2%-43,264pp | |
| Net margin | -101.1%+544pp | -644.8%+14,054pp | -14,698.7%+58,642pp | -73,341%-43,892pp | |
| Returns | |||||
| Return on equity | -39.7%+128pp | -167.7%+0.8pp | -168.5%-80.1pp | -88.4%-23.4pp | |
| Return on invested capital | -33.5%+75.4pp | -108.9%+4.6pp | -113.4%+0.6pp | -114.1%+73.4pp | |
| Efficiency | |||||
| Asset turnover | 0.2×+0.1× | 0.1×+0.1× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 4.9×-0.6× | 5.4×-0.2× | 5.6×-0.5× | 6.1×+2.1× | |
| Leverage | |||||
| Debt-to-equity | 0.6×-0.1× | 0.7×-0.4× | 1.1×+0.7× | 0.5×+0.5× | |
| Per Share | |||||
| Book value per share | $0.30-35.0% | $0.46+8.3% | $0.42-40.4% | $0.71-9.4% | |
| Valuation | |||||
| Market capitalization | $986.12M+262% | $266.96M-28.8% | $374.73M+4.0% | $360.47M-38.6% | |
| Price / sales | 14.2×+5.4× | 8.6×-302× | 311×-2,282× | 2,593.3×+625× | |
| Price / book | 4.9×+2.6× | 1.8×-2.2× | 4×+0.9× | 3.1×-2.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Lexicon Pharmaceuticals's profit margins?
- Lexicon Pharmaceuticals (LXRX) runs a 99.5% gross margin and a -34.8% operating margin, with a -37.5% net margin.
- Where do Lexicon Pharmaceuticals's ratios come from?
- Every ratio is computed from Lexicon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
